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ABSTRACT 
 
Background and rationale: Inhaled nitric oxide (iNO) is recommended for the 
treatment of severe persistent pulmonary hypertension of the newborn (PPHN) 
because it reduces the need for extracorporeal membrane oxygenation (ECMO). 
There is insufficient evidence that iNO reduces mortality in the absence of ECMO. 
Although neonates in some South African public hospitals have access to iNO, 
ECMO is not available. Oral sildenafil can be effective in settings where iNO is not 
available, but its effect on outcome and cost of treatment in this setting have not been 
described.  
The literature review in the first part of this thesis describes five studies reporting 
short-term outcomes of PPHN in the absence of ECMO. No studies from South 
Africa were identified. Only two studies described outcomes after iNO – the co-
administration of Sildenafil with iNO was only reported in one small study. There 
were insufficient published data to guide management in settings where ECMO is not 
available. 
Aim: To describe a cohort of term and near term neonates with PPHN who were 
treated with iNO, with or without sildenafil, in a tertiary neonatal unit in South Africa  
Objectives: (i) to describe the characteristics at birth, the clinical course, and short-
term outcomes; (ii) to determine if any variables were associated with mortality; (iii) 
to describe the relationship between the use of sildenafil and cost of care, represented 
by the duration of intubation and iNO use; and (iv) to describe the frequency of 
sildenafil prescription. 
Methods. A retrospective review was carried out on folders of neonates with PPHN 
who were treated with iNO in Groote Schuur Hospital, Cape Town, South Africa, 
between January 2010 and December 2014. 
Results. Forty neonates were included – most were full term (85%). Meconium 
aspiration syndrome (MAS) was the commonest cause of PPHN (50%), followed by 
intrapartum hypoxia (20%), sepsis (17.5%), pulmonary hypoplasia (7.5%) and 
idiopathic (5%). Fourteen neonates (35%) died.  Pulmonary hypoplasia and 
pneumothorax were associated with mortality (p=0.037 and p=0.004 respectively). An 
FiO2 of 1.0 and an iNO dose of ≥ 20 ppm at 24 and 48 hours respectively, both 
predicted death (specificity 89% vs. 100%, sensitivity 67% vs. 43% and p=0.003 vs. 
p=0.007 respectively). Sildenafil was prescribed more often after 2011 (83% vs. 65%) 
and was associated with increased survival (p=0.018) – early administration was 
associated with a shorter time to extubation (p=0.012) and a shorter course of iNO 
(p=0.044).  
Conclusion. The treatment of PPHN with iNO in the absence of ECMO was 
associated with high mortality, particularly in neonates with congenital lung 
abnormalities. The FiO2 and iNO requirements at 24 and 48 hours respectively could 
be used to identify neonates who are unlikely to benefit from continued treatment. 
Sildenafil was prescribed with increasing frequency during the study. The 
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combination of iNO with sildenafil was associated with more cost-effective care and 
improved short term outcomes. These findings provide a potential basis for cost-
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Persistent pulmonary hypertension of the newborn (PPHN) is an important neonatal 
condition associated with substantial morbidity and mortality - it is estimated that 
PPHN accounts for up to 10% of neonatal intensive care unit (NICU) admissions in 
the Western World, and has a mortality of 4 - 33%, depending on the setting.[1] 
PPHN is defined as: ‘the failure of the normal circulatory transition that occurs after 
birth’[2,3]; it is characterized by excessive right-to-left extrapulmonary shunting of 
blood, often associated with severe hypoxaemia.[3] Pulmonary hypertension 
complicates the clinical course of more than 10% of all neonates with respiratory 
failure – poor cardiac output and shock are frequently associated in severe cases.[1]  
Various approaches have been suggested for the classification of PPHN - one 
common approach is to classify it into three categories[3]: 
1) Secondary PPHN with abnormally constricted pulmonary vasculature due to lung 
parenchymal diseases – such as meconium aspiration syndrome (MAS), hyaline 
membrane disease (HMD), or pneumonia; or transient pulmonary artery 
vasoconstriction following hypoxaemia, particularly intrapartum hypoxaemia; 
2) Idiopathic PPHN with normal lung parenchyma and remodeled pulmonary 
vasculature;  
3) Primary PPHN with hypoplastic pulmonary vasculature as seen in congenital 
diaphragmatic hernia.  
Secondary PPHN is the commonest type (60 - 80%), whilst idiopathic pulmonary 
hypertension is responsible for only 10 - 20% of all infants with PPHN, but there is 
significant overlap between the groups.[3]  
Inhaled nitric oxide (iNO) is recommended for the treatment of severe PPHN due to 
reversible causes (secondary PPHN), when the oxygenation index (OI) is > 25 – this 
recommendation is based on the reduction in the need for extracorporeal membrane 
oxygenation (ECMO) in treated infants.[4] However, iNO is very expensive,[5] and 
there are very limited data describing outcomes following the use of iNO for PPHN in 
settings where ECMO is not available – such as South African state hospitals.  
Since the evidence for efficacy of iNO is based on the availability of ECMO, the 
outcomes of neonates after being treated with iNO in settings where ECMO is not 
available should be studied to monitor the appropriateness and cost effectiveness of 
this treatment.  
 
1.2 AIM AND OBJECTIVES 
 
The aim of this literature review was to identify and compare the outcomes of studies 
of cohorts of neonates with acquired and idiopathic PPHN in settings where ECMO 
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The objectives of the review were to:  
i) describe the diagnostic criteria used to identify PPHN; 
ii) describe the mortality associated with PPHN; 
iii) describe the demographic and clinical characteristics at birth of neonates with 
PPHN; 
iv) describe the causes of PPHN;  
v) describe the treatment modalities for PPHN; 
vi) describe the complications and/or non-causal morbidity associated with PPHN: 
 
This review focused specifically on short-term outcomes to provide reference data for 




1.3.1 Data source and search strategy 
 
PubMed was searched from the time that the database started, in 1946, until 10 March 
2017, using the following search string:  
((((((((persistent pulmonary hypertension) AND (neonat* OR newborn)) AND 
(outcome OR morbidity OR mortality OR demographic))). Foreign-language studies 
were excluded.  
 
1.3.2 Inclusion and exclusion criteria 
 
Papers describing cohorts of neonates with acquired and idiopathic PPHN that met the 
following inclusion criteria were included: 
i) The population studied consisted of neonates diagnosed with PPHN; 
ii) The study described demographic and/or clinical characteristics, causes of 
PPHN, and outcome at hospital discharge; 
iii) The study included term infants (studies describing lower gestation in addition 
to term infants were not excluded); 
iv) The study cohort was managed in a setting where ECMO was not available; 
v) The study reported inclusion/diagnostic criteria; 
 
The following types of studies were excluded: 
a) Studies which included predominantly non-pulmonary causes of PPHN (e.g. 
cardiac causes, or congenital diaphragmatic hernia) 
b) Studies focused exclusively on single, isolated causes of PPHN (e.g. idiopathic 
PPHN). 




1.4.1 Literature review process 
 
The search string identified 720 articles. Twenty-one potentially relevant studies were 
identified after title review. Eleven studies were excluded after abstract review. Two 
further studies were excluded because the full texts were not available either online or 
through the university library – these two were the oldest of all the studies and were 
published in the 1980s.[6,7] The full texts of eight studies were reviewed and when it 
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was not clear from the text or setting whether ECMO was available, the authors were 
emailed for clarification. Three further studies were excluded: one small study was 
excluded because it only focused on the medications received by the cohort[8]; the 
second study  focused predominantly on long-term outcomes[9]; and the third study 
was excluded because the author confirmed that although ECMO was not mentioned 
in the study, the majority of infants would have had access to it.[10] 
 
The remaining five studies formed the basis of this review: one study was from North 
America[11] (ECMO may have been available, but the availability of ECMO was not 
stated and the email address for the corresponding author was no longer valid), three 
from Asia,[12-14] and one from North Africa.[15] All were peer-reviewed. The process 
of identification of studies for inclusion is shown in Figure 1.1. 
 
 






	 	 	 4	
 
The study types, years and dates of publication of the included studies are shown in 
Table 1.1. 
 
Table 1.1: Type and dates of included studies included in review 
USA – United States of America 
 
 
1.4.2 Diagnosis of PPHN 
 
There was wide variation amongst the studies in the diagnostic criteria for PPHN. The 
different criteria are summarized in Table 1.2.  
 
One study relied predominantly on clinical criteria,[12] the others used a combination 
of clinical criteria and echocardiography.[11,13-15] The clinical diagnostic criteria 
differed between studies: one used a PaO2 difference in the pre- and post-ductal limbs 
of 15 mmHg,[13] another used 20 mmHg.[12] Similarly, one study utilised a saturation 
differential between the pre- and post-ductal limbs of 5%,[11] another used 10%.[12] 
Echocardiographic criteria also varied: one study only required evidence of 
pulmonary hypertension (a peak velocity of the tricuspid regurgitation jet of > 40 
mmHg),[14] while the others required visual demonstration on echocardiogram of 














Author (publication date) Type of Study Setting  
(study date) 




Hernandez-Diaz (2007) [11] Retrospective case-
control study 
Massachusetts, USA 
(1998 – 2003) 








Nakwan (2015) [12] Retrospective cohort 
study 
Hat Yai, Thailand  
(2010-2014) 
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The demographic and clinical characteristics, causes, treatment and associated 
morbidity of PPHN are shown in Table 1.3.  
 
The mortality rate ranged from 3 to 39.4% - it was highest in lower socio-economic 
settings, ranging from 25 to 39.4%. The only study with a mortality of less than 25% 
took place in USA, and it was not clear whether ECMO was used in this study.[11]  
 
 
1.4.4 Demographic and clinical characteristics at birth 
 
Only two studies described the proportion of out born patients,[12,13] which ranged 
from 27.7 to 75.9%. Sex was documented in four studies[12-15] - the majority of babies 
born with PPHN were male. The difference in sex proportions reached statistical 
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Gestational age was specifically reported on in four studies.[11-14] The other study 
stated that all babies were term without further detail.[15] Two studies only included 
term children ( > 37 weeks),[12,15] but in the other three studies, the majority of the 
infants were also term (69% - 84%).[11,13,14] Prematurity was significantly associated 
with developing PPHN in the study that examined it.[11] Most infants had a birth 
weight above 2500 g. A low weight at birth was not independently associated with 
PPHN, unless the infant was premature.[11] 
 
The mode of delivery was documented in four studies.[11,12,14,15] Caesarean section 
rates ranged from 42.9% to 64.6%, and two studies showed a significant association 
between caesarean section and PPHN.[11,15] None of the studies commented on 
whether the caesarean sections were elective or emergency in nature. 
 
The need for resuscitation at birth, in the form of intermittent positive pulmonary 
ventilation, was only recorded in two studies[12,14] and in neither study was a 
significant association found with PPHN. The incidence of ‘Birth asphyxia’ was 
reported in two studies[13,14]; it ranged from 24% to 40%, but the term was not clearly 
defined. 
 
1.4.5 Causes of PPHN 
 
While the following pathologies are described in the literature as causes of PPHN, 
and referred to the same in this review, it is difficult to determine if they are causes or 
associated morbidities. 
 
The most common cause of PPHN in four of the studies was MAS.[12-15] This was 
diagnosed by finding evidence of meconium-stained liquor (stained fingernails, 
stained skin, and/or meconium on the vocal cords) and respiratory distress - the 
proportion of affected infants ranged from 24.4 to 54.6%. The only study that 
included preterm infants found HMD to be the most common cause.[11]  
 
Although sepsis was an important cause of PPHN in most studies, accounting 
for 13.8 - 43.8% of cases, only two studies provided diagnostic criteria for it.[11,14] 
Sepsis was diagnosed in one study on the basis of a suggestive history combined with 
abnormal septic markers in the serum,[14] in the other study, sepsis was described as 
suspected or culture-proven.[11]  
 
Only three studies reported on congenital pneumonia (defined as having a septic risk 
factor, combined with respiratory distress and suggestive findings on Chest X-ray) as 
a separate entity[11,12,15] (the other studies included it in the ‘sepsis’ category), but it 
nevertheless remained an important cause of PPHN, accounting for 15.1 - 31.3% of 
cases. 
 
Hyaline membrane disease accounted for 0.8 - 50.4% of cases of PPHN, but in the 
studies that only included term infants, HMD was an infrequent cause of PPHN. 
 
Only two studies reported on idiopathic PPHN[12,13] – it was an uncommon cause, 
accounting for 0.8 - 7% of cases.  
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1.4.6 Treatment Modalities 
 
The use of mechanical ventilation (defined as being ventilated via an endotracheal 
tube using a mechanical ventilator) varied greatly between studies – from as low as 
20% in one study,[14] to 100% in two others.[11,13] The percentage of infants requiring 
high-frequency oscillatory ventilation (HFOV) ranged from 9.4% to 80.7%. One 
centre did not provide HFOV.[14] Access to iNO was only reported in two 
studies.[11,12] In one study iNO was used frequently (67%),[11] the other far less so 
(31%).[12] Neither study reported the criteria that were used to determine which 
patients were given iNO, nor if the oxygenation index ([inspired concentration of 
oxygen (%) x mean airway pressure]/post-ductal arterial partial pressure of oxygen in 
mmHg) was utilised. Only one study reported on outcome[12] – iNO was used in a 
higher proportion of those who died  than in survivors (p=0.01), but the association 
may reflect illness severity rather than lack of effect. 
 
Sildenafil was used in two studies[12,15] – it was given to 50 - 69% of patients, and in 
one study both iNO and sildenafil were available.[12] In one study, the administration 
of intragastric sildenafil was used more frequently in those who did not survive than 
in those who did (p<0.01).[12] In the other, half of the patients were randomly assigned 
the intragastric sildenafil, and 62.5% of patients who received it were reported to 
‘show improvement’, but this was not clearly defined.[15] 
 
Tolazoline (an alpha receptor antagonist which causes peripheral arterial dilatation), 
was used in one study in 83% of the neonates, and an improvement in their 
hypoxaemia was reported in 67% of them, but this improvement was not defined, nor 

































The use of inotropic agents was variably reported. Only three studies stated that 
inotropic agents were used in the treatment centres[12,13,15]; of these, only two 
specified which inotropic agent was used. One centre made use of dopamine 
exclusively[13]; while the other used dopamine (all patients), adrenaline (98.3%), 
dobutamine (9.2%) and nor-adrenaline for a minority of their neonates (6.7%).[12] 
Only one study investigated an association between mortality and inotrope use – 
treatment with nor-adrenaline was associated with increased mortality (p=0.03),[12] 




Only one study reported on the short-term complications or additional morbidity 
associated with PPHN[12] – in this study, acute kidney injury (AKI) and pneumothorax 
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Table 1.3: Demographic and clinical characteristics, causes, treatment and 
associated morbidity of PPHN 
 - Variable not reported in the study;  - Data unclear. Study mentions the presence of variable, but does not 
quantify or elaborate,  HFOV – high frequency oscillatory ventilation; HMD – hyaline membrane disease ; IPPV – 





There are very few published studies describing the short-term outcomes of neonates 
with PPHN in centres which do not have access to ECMO. Only one study from 
Africa (Egypt) was identified.[15] Diagnostic criteria varied widely and the mortality 
ranged from 25 to 39% in centres where ECMO was definitely not available. 
Mortality was 3% in one North American study where ECMO may have been 
used.[11] Clinical characteristics, treatment and morbidities varied widely and were 
inconsistently reported. 
 
The variable mortality rate, with the lowest mortality occurring in a high-income 













N 119 79 32 377 29 
Outborn n (%) 33 (27.7)    22 (75.9) 
Male n (%) 75 (63) 57 (72.1) 18 (56.2)  18 (62.1) 
Gestational Age 
Mean GA or % term 39 wks 77%   84% 37.1 wks 
Birth-weight (g) 
Mean or % >2500 g 3044   92% 2707 
Caesarean Section n 
(%) 51 (42.9) 43 (54.2) 20 (64.6) 231 (61.3)  
IPPV at birth n (%) 2 (1.7) 35 (44.2)    
Birth Asphyxia n 
(%)  32 (40.5)   7 (24.1) 
Sepsis n(%) 22 (18.5) 23 (29.1) 14 (43.8) 122 (32.4) 4 (13.8) 
MAS n (%) 65 (54.6) 28 (35.4) 16 (50) 179 (47.5) 8 (27.6) 
Pneumonia n (%) 18 (15.1)  10 (31.3) 116 (30.8)  
Idiopathic n (%) 1 (0.8)    2 (6.9) 
HMD  n (%) 1 (0.8) 11 (13.9) 6 (18.8) 190 (50.4) 5 (17.2) 
Mechanical 
Ventilation n (%) 75 (63) 16  (20) 12 (37.5) 377 (100) 29 (100) 
HFOV 96 (80.7) 16  (20) 3 (9.4) 264 (70) 4 (13.8) 
Inhaled Nitric Oxide 37 (31.1) 0 0 253 (67.1) 0 
Sildenafil 83 (69.7) 0 16 (50) 0 0 
Tolazoline  0 0 0 0 24 (82.7) 
Inotropes 119 (100) 0   27 (93) 
Pneumothorax 57 (49)     
Acute Kidney injury 31 (26)     
Mortality n (%) 47 (39.4) 21 (26.6) 8 (25) 11 (3) 8 (27.6) 
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country with possible access to ECMO, is similar to the mortality quoted in other 
global reviews (3 - 33%).[1] The only study with mortality < 25% collected data from 
three states in North America where ECMO was probably available – ECMO use was 
not specifically described and the corresponding author could not be contacted.[11] 
The higher mortality in middle-income countries may have been due to limited 
equipment, staff and/or specifically due to the lack of ECMO. A meta-analysis of 
systematic reviews found that the mortality in infants with severe PPHN, in the 
absence of CDH, decreased from 48% in control infants to 16% in the group treated 
with ECMO,[16] and mortality in neonates with PPHN was reduced from 28% to 11% 
when ECMO was introduced in a centre in Chile (an upper middle income 
country).[17]  
 
Two of the studies reported that many patients with PPHN were not born in a tertiary 
setting[12,13] – this may have increased their mortality due to: (a) the limited treatment 
they received in transit and/or (b) the length of time it took for the transfer to take 
place. Staff shortages were specifically mentioned as being a barrier to providing 
quality health care.[12,14] In one hospital, a single neonatologist and a single 
cardiologist were responsible for over 120 infants. There was no consistent 
relationship between mortality and the extent of iNO use.  
 
Demographic and clinical criteria at birth were not consistently reported across all 
studies. The majority of infants with PPHN were male and previous studies have 
shown that being female is protective against developing HMD (a potential cause of 
PPHN), due to advanced fetal lung maturity.[18,19] The association found in one of the 
studies between late prematurity and PPHN has been attributed by some authors to a 
higher rate of HMD after delivery without antenatal steroids in these neonates, and a 
higher incidence of sepsis, compared to term babies.[20-22] Birth weights were similar 
across the studies – this is not unexpected, as most of the studies excluded premature 
babies from their analysis. No associations were found between birth weight and 
mortality when gestational age was taken into consideration.[11] 
 
Previous studies have identified Caesarean section as an independent risk factor for 
the development of PPHN.[23] There is echocardiographic evidence of decreased 
pulmonary vascular resistance following vaginal delivery compared to neonates born 
by elective Caesarean section,[24] - this may be related to prostaglandin release 
induced by labour.[25] Other authors have proposed that catecholamine release during 
normal vaginal deliveries may improve lung compliance, placing those delivered via 
Caesarean section at risk of developing PPHN.[26] Most of the babies with PPHN in 
this review were delivered via Caesarean section, and some of the smaller studies 
described a significant association with PPHN and Caesarean sections.  
 
Although MAS was the most common associated morbidity or cause of PPHN[12,13,15]; 
sepsis/pneumonia, birth asphyxia, and HMD were also significant causes. Very few of 
the studies considered the potential for overlap between the causes, which other 
authors have highlighted,[3] and distinguishing cause from association is difficult in 
this setting. It is also possible that the diagnosis of MAS was over-called because in 
many of the studies, if a neonate showed signs of respiratory distress, evidence of 
exposure to meconium-stained liquor (as evidenced by staining of the skin or 
fingernails) was accepted as diagnostic of the condition, without further investigation.  
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Sepsis may also have been over-diagnosed in several studies, for two reasons: first, 
only one study reported separately those patients in whom sepsis was a risk (e.g. born 
to a mother with chorioamnionitis), and those in whom it was confirmed on blood 
culture[11]; second, some of the studies relied on septic markers rather than blood 
culture, but these have inadequate sensitivity and specificity for neonatal sepsis,[28] 
especially in the first 12 hours of life, where both MAS and perinatal hypoxia can 
raise C-Reactive Protein levels.[28] Some studies documented congenital pneumonia 
separately from sepsis[11,12,15] – but if congenital pneumonia is included in the 
diagnosis of sepsis then the most common cause  (or associated morbidity) of PPHN 
in this review, is sepsis at birth. 
 
Idiopathic PPHN is estimated to occur in 10 - 20% of cases of PPHN,[3] but only two 
studies in this review reported on it.[12,13] This suggests that it may be a condition that 
is being under diagnosed, and some reported causes (e.g. MAS) might be associations 
rather than causal.  
 
There was substantial variation in the treatments offered across the studies, in keeping 
with the resources available. Ventilation with HFOV is a longstanding 
recommendation[29] but not all centres offer it and many hospitals in poorly-resourced 
environments lack sufficient conventional ventilators to meet their patients’ needs. 
This explains the vast discrepancies in both the number of patients ventilated and 
those who received HFOV, and may also be a contributing factor to the high mortality 
in some of the studies. 
 
Only two of the studies included centres that offered iNO,[11,12] probably due to the 
very high cost of the treatment, and there was insufficient description of treatment 
protocols and weaning strategies. The Cochrane Collaboration advises using it in term 
or near-term, mechanically ventilated neonates with an OI > 25.[4] Up to 30% of 
infants with PPHN will not respond to iNO,[31] but no mention was made in either 
study about how these patients were identified or managed. Prognostic criteria and 
potential interactions with other therapies were also not described in these studies.  
 
Sildenafil, a phophodiesterase inhibitor, is recommended as adjunctive therapy for 
PPHN in resource-limited settings,[30] due to the cost of iNO.[31] It has been shown to 
both reduce mortality and improve oxygenation,[31] but only two of the studies made 
use of it,[12,15] while experimental vasodilators such as tolazoline and magnesium 
sulphate were used in some other studies.[13,15] The mixed association between 
sildenafil use and mortality in the studies is difficult to assess because the sample 
sizes were both small, but the results are not in keeping with meta-analysis that 
demonstrates clear benefit.[31] The timing of the sildenafil administration, and its 
effects on mean blood pressure (MBP), were also not reported on. Although there is 
concern that sildenafil may lower MBP, and individual case studies have shown this 
effect,[32] other small studies indicate that in the doses generally provided 
(1.5 - 4.5mg/kg/dose), sildenafil has no major effect on it.[33] In addition, neither study 
in this review looked at any additional benefits the sildenafil provided (such as 
improvement in oxygenation). Only one study used both sildenafil and iNO,[12] but an 
analysis of their interaction was not done. In animal models, the combination of iNO 
at 20 parts per million (ppm) and intravenous sildenafil (2 mg/kg over 2 hours) 
produced significant pulmonary artery vasodilatation, but with concomitant systemic 
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vasodilatation and an unacceptable loss of systemic oxygenation.[34] In human infants 
post cardiac surgery, the combination of iNO at 20 ppm and intravenous sildenafil 
(0.35 mg/kg over 20 minutes), either before or after the iNO, resulted in systemic 
hypotension and impaired tissue oxygenation.[35] 
 
Only one study commented on complications or non-causal morbidities[12] – acute 
kidney injury and pneumothorax were independently associated with poor outcomes. 
However, due to the exploratory nature, and the large number of variables examined 
in the study, the ‘significant’ differences may have been detected by chance.  
 
A number of general limitations make the findings of this review difficult to interpret: 
first, most studies were small, and the studies which took place in single centres may 
have been prone to referral bias; second, there was substantial heterogeneity of not 
only the type of patients studied, but also the treatment modalities and resources 
available; third, the variation in diagnostic criteria suggests that certain studies may 
have either over- or under-diagnosed cases of PPHN and there is likely to be variation 




There are inadequate data describing the mortality of neonates with PPHN in settings 
where ECMO is not available; but the mortality is substantially higher than settings 
where ECMO is available, even if iNO is available. In particular, there are insufficient 
data to guide management of neonates with PPHN in settings where ECMO is not 
available but iNO and Sildenafil are available; the severity of PPHN needs to be 
quantified more objectively; and more data are needed to determine which 
demographic and clinical characteristics at birth or treatment modalities are associated 
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ABSTRACT 
 
Background. There is insufficient evidence that inhaled nitric oxide (iNO) reduces 
the mortality of persistent pulmonary hypertension of the newborn (PPHN) when 
extracorporeal membrane oxygenation (ECMO) is not available. Some hospitals in 
South Africa have access to iNO for PPHN, but not ECMO. Sildenafil is an 
alternative to iNO, but there are insufficient data to inform management of neonates 
treated with iNO, with or without sildenafil, in this setting. 
 
Objectives. (i) To describe the characteristics at birth, clinical course, and short-term 
outcomes of a cohort of term and near term neonates with PPHN, who were treated 
with iNO, with or without sildenafil, in a tertiary neonatal unit; (ii) to determine if any 
variables were associated with mortality; (iii) to describe the relationship between the 
use of sildenafil and cost of care, represented by the duration of intubation and iNO 
use; and (iv) to describe the frequency of sildenafil prescription. 
 
Methods. A retrospective review was carried out on folders of neonates with PPHN 
who were treated with iNO in Groote Schuur Hospital, Cape Town, South Africa, 
between January 2010 and December 2014. 
 
Results. Forty neonates were included; 85% were full term. Meconium Aspiration 
Syndrome (MAS) was the commonest cause of PPHN (50%), followed by 
intrapartum hypoxia (20%), sepsis (17.5%), pulmonary hypoplasia (7.5%) and 
idiopathic (5%). Fourteen neonates (35%) died. Pulmonary hypoplasia and 
pneumothorax were associated with mortality (p=0.037 and p=0.004 respectively). An 
FiO2 of 1.0 and an iNO dose of ≥ 20 ppm at 24 and 48 hours respectively, predicted 
death (specificity 89% vs. 100%, sensitivity 67% vs. 43% and p=0.003 vs. p=0.007 
respectively). Sildenafil was prescribed more often after 2011 (83% vs. 65%) and was 
associated with increased survival (p=0.018) – early administration was associated 
with a shorter time to extubation (p=0.012) and a shorter course of iNO (p=0.044).  
 
Conclusion. The treatment of PPHN with iNO in the absence of ECMO was 
associated with high mortality, particularly neonates with congenital lung 
abnormalities. The FiO2 and iNO requirements at 24 and 48 hours respectively could 
be used to identify neonates who are unlikely to benefit from continued treatment. 
Sildenafil was prescribed with increasing frequency during the study. The 
combination of iNO with sildenafil was associated with more cost-effective care and 
improved short term outcomes. These findings provide a potential basis for cost-
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2.1 BACKGROUND 
 
Persistent pulmonary hypertension (PPHN) occurs due to a failure of the circulatory 
transition that should occur after birth; it is characterized by abnormally constricted 
pulmonary vessels and excessive right-to-left extra-pulmonary shunting of blood, 
often associated with severe hypoxaemia.[1] It is estimated that PPHN accounts for up 
to 10% of neonatal intensive care unit (NICU) admissions, and has a mortality rate of 
4–33%, depending on the setting.[2] 
The commonest causes of PPHN are secondary; due mainly to intrapartum hypoxia, 
or lung pathologies such as meconium aspiration syndrome (MAS), hyaline 
membrane disease (HMD) and pneumonia.[3] Other causes are: idiopathic PPHN with 
normal lung parenchyma and remodeled pulmonary vasculature, and primary PPHN 
with hypoplastic pulmonary vasculature.[3] 
Inhaled nitric oxide (iNO), a pulmonary artery vasodilator, is recommended by the 
United States Food and Drug Administration (FDA) and the European Medical 
Equipment Agency for the treatment of term and near-term neonates less than 14 days 
old, with severe PPHN.[4,5] However, meta-analysis of eight randomised control trials 
demonstrated that although iNO significantly decreased the need for extracorporeal 
membrane oxygenation (ECMO) in newborns with secondary PPHN, it did not 
decrease mortality.[6] 
Neonates in some South African public hospitals have access to iNO, but ECMO is 
not available; there are few published data on mortality of neonates in this setting and 
data are predominantly derived from retrospective studies.[7-11] Despite the availability 
of iNO in two of these studies, the mortality was usually high (25–40%).[9,10] Only 
one study (in a developed setting) reported a mortality of less than 25%, but the 
availability of ECMO in this study was not clearly stated.[8] The sample sizes and 
definitions in these studies were too variable to determine outcome predictors and 
treatment efficacy.[10,11] Permission from the Medicines Control Council (MCC) and 
parental consent are required to use iNO in South Africa, and it is expensive. A study 
in North America in 2009, estimated the cost of iNO to range from United States (US) 
$ 1 200 to US $ 24 000 per patient.[12]  
At the time of writing, there are no published reports examining the use and cost of 
iNO for PPHN in South Africa. A Cochrane systematic review and meta-analysis 
concluded that sildenafil, a phosphodiesterase-five inhibitor which induces pulmonary 
vasodilatation, could be used in settings where iNO is not available, but the use of 
iNO and sildenafil together requires further research.[13] 
This study aimed to describe a cohort of neonates with PPHN, who were treated with 
iNO, with or without sildenafil, between January 2010 and July 2014 in a tertiary 
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2.2 OBJECTIVES  
 
(i) To describe the characteristics at birth, the clinical course, and short-term 
outcomes; 
(ii) To determine if any variables were associated with mortality; 
(iii) To describe the relationship between the use of Sildenafil and cost of care, 
represented by the duration of intubation and iNO use; and 






The study was a descriptive, retrospective cohort, folder review, from which baseline 
data were collected. A convenience sample was used, based on a period when data 
were prospectively entered into a register that was maintained to comply with MCC 
requirements, and for cost-audit purposes. Neonates were identified using this register 
and further data were extracted from the folders. The register and retrospective folder 
review were approved by the Human Research Ethics Committee of the Health 




2.3.2 Setting and participants 
 
The GSH Neonatal Unit is one of two public tertiary neonatal units within the 
Western Cape Province, South Africa. This 75-bed unit has approximately 200 
admissions per month and is the tertiary referral centre for the west metropole area. 
A Bedfont NOxBOX (Bedfont® Scientific Ltd, Kent) was used to monitor and 
administer iNO, according to the unit protocol, in neonates with PPHN meeting all of 
the following criteria: 
i) Gestation ≥ 35 weeks; 
ii) Oxygen saturation < 90% at FiO2 > 0.8, despite ventilation with tidal volumes of 
4-6ml/kg or treatment with high frequency oscillation ventilation (HFOV); 
iii) Suspected PPHN with right to left shunting based on echocardiography and/or 
clinical signs (hypoxaemia unresponsive to increasing concentrations of FiO2, but 
responsive to increased systemic blood pressure or a pre- and post-ductal oxygen 
saturation differential of ≥ 10%); 
iv) Absence of cyanotic heart disease and known severe congenital anomalies – 
neonates with congenital diaphragmatic hernia (CDH) were excluded from 2011 
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Neonates were included in the study as follows: 
Inclusion criteria: Neonates meeting the above criteria and treated with iNO for 
PPHN at GSH between January 2010 and December 2014. Data for oxygenation 
index were unavailable, and this was not used. 
Exclusion criteria: Neonates whose hospital records were not adequate / available. 
Treatment with iNO was started at 20 parts per million (ppm); weaning commenced 
when a sustained fall in FiO2 occurred and/or when FiO2 was < 0.6. Sildenafil (started 
at 0.5 mg/kg/dose 6 hourly via intragastric tube, and increased to a maximum of 2 
mg/kg/dose, based on response), was used in some infants, particularly those with 
stable blood pressures, or who were failing to wean off iNO. However, sildenafil was 
used more frequently after 2011 when an internal review showed unsustainable use of 
iNO relative to the budget.  
 
2.3.3 Data collection, outcome measures and analysis 
 
Data were collected on a case record form and analysed using Stata v12 (Stata 
Corporation, Texas, United States of America).   
Characteristics at birth included: birth weight; gestational age (late preterm was 
defined by gestational age at birth of 35–36 completed weeks based on Ballard or 
early ultrasound); place of birth; resuscitation at birth and Apgar scores; blood gas 
parameters in the first hour of life; Human immunodeficiency virus (HIV) exposure; 
and the presence of sepsis risk factors (prolonged rupture of membranes > 18 hours, 
chorioamnionitis or maternal sepsis).  
The primary cause of the PPHN was recorded using the following definitions: 
‘mortality’ was defined as death due to PPHN or its immediate complications, 
‘confirmed sepsis’ was defined as the growth of a pathological organism on a blood 
culture taken within the first 72 hours of life; ‘congenital pneumonia’ was defined as 
the presence of respiratory distress, sepsis risk at birth and suggestive chest X-ray 
findings; ‘presumed sepsis’ was defined as being clinically unwell in the presence of 
elevated septic markers but no positive blood culture and a normal chest X-ray; ‘any 
sepsis’ included infants with confirmed or presumed sepsis and those with congenital 
pneumonia; ‘intrapartum hypoxia’ was defined as the need for resuscitation at birth 
and suggestive maternal history, or a base deficit in the first hour of life of 10 or 
more; ‘MAS’ was defined as the presence of respiratory distress, meconium-stained 
liquor and suggestive X-ray findings; ‘pulmonary hypoplasia’ was defined as having a 
small lung capacity relative to ventilator support – this was a clinical judgement. 
The clinical course and short-term outcomes were recorded, including: inotrope 
treatment; surfactant treatment; hydrocortisone treatment; treatment with high 
frequency oscillatory ventilation (HFOV); FiO2 at initiation, 12 hours, and 24 hours; 
iNO dose at initiation, 12 hours, 24 hours and 48 hours; duration of iNO treatment; 
duration of intubation; sildenafil use and timing of initiation relative to iNO; presence 
of a pneumothorax; pneumonia, nosocomial sepsis and presumed nosocomial sepsis 
(defined as stated above for pneumonia, sepsis and presumed sepsis, but presenting at 
≥ 72 hours of life); intraventricular haemorrhage (IVH); hypoxic ischaemic 
encephalopathy (HIE) – defined as the presence of clinical seizures or an abnormal 
amplitude-integrated electroencephalogram (aEEG) in a neonate with a history of 
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perinatal hypoxia; and mortality. Sildenafil use was divided into three groups: ‘none’; 
‘early’ (before or at the same time as initiation of iNO); and ‘late’ (after iNO had been 
commenced). 
Association with mortality was analysed using Fisher’s exact test for categorical 
variables, and student’s t-test or the Kruskal Wallis test for normally and non-
normally distributed continuous variables respectively. Receiver operator curve 
(ROC) analysis was used to determine threshold levels of iNO dose and FiO2 that 
predicted mortality. The diagt statistical module was used to calculate sensitivity, 
specificity, and likelihood ratio (LR).  The relationship between sildenafil use, 
duration of mechanical ventilation and iNO use was explored using the Kruskal 
Wallis test. P values of < 0.05 were considered significant. 
No formal cost-saving analysis was performed, so proxy-measures, in the form of 
duration and concentration of iNO use (combined with the known cost of iNO as 





A total of 43 patients met inclusion criteria – adequate records were not available for 
three neonates. Data for the remaining 40 neonates were analysed; 26 survived to 
hospital discharge and 14 died. The survivors were mechanically ventilated for a 
median period of 4.5 (IQR 3–7) days. 
 
2.4.1 Characteristics at birth and causes of PPHN 
 
The characteristics of the neonates and causes of PPHN are shown in Table 2.1. Most 
neonates were term gestation (85%), with a normal birth weight (2970±560 g) and the 
majority of them were out-born (78%). There were no significant differences in the 
characteristics at birth between survivors and non-survivors.   
Meconium Aspiration Syndrome (MAS) was the commonest cause of PPHN (50%), 
followed by intrapartum hypoxia (20%), sepsis (18%), pulmonary hypoplasia (8%) 
and idiopathic (5%). However, only one of the seven neonates with a diagnosis of 
sepsis had a positive blood culture. Twenty neonates (50%) had a low 5-minute Apgar 
score and/or received assisted ventilation at birth, but only 13 of these neonates and 
seven in the rest of the cohort had a blood gas within the first hour of life. Although 
intrapartum hypoxia was the suspected primary cause of PPHN in eight neonates, at 
least 10 of the 20 neonates with MAS also met criteria for intrapartum hypoxia. 
Pulmonary hypoplasia was significantly associated with death (p=0.037) – all three 
affected neonates died before 24 hours of age. The causes of pulmonary hypoplasia 
were CDH, severe oligohydramnios associated with renal failure, and idiopathic. Both 
the neonates with idiopathic PPHN were term infants – one was underweight for 
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Table 2.1: Characteristics at birth and causes of PPHN 
 Variable All (N=40) Alive (N=26) Dead (N=14) P-Value 
 Data are n(%) / mean (±SD)*  
Characteristics at birth  
Birth-weight in grams 2970 (±560.4) 2966 (±524.9) 2977.5 (±642) 0.955 
Late preterm 6 (15) 6 (23) 0 0.074 
Inborn 13 (32.5) 10 (38.5) 3 (21.4) 0.316 
5 minute Apgar <7 16 (40) 11 (42.3) 5 (35.7) 0.746 
Assisted ventilation at birth 17 (42.5) 9 (34.6) 8 (57.1) 0.198 
Low Apgar or ventilation at 
birth 20 (50) 12 (46) 8 (57) 0.741 
Blood Gas in 1st hour 20 (50) 11 (42.3) 9 (64.3) 0.320 
Lowest pH in 1st hour 7.1 (±0.1) (n=20) 
7.1 (±0.2) 
(n=11) 7.2 (±0.1) (n=9) 0.357 





(n=11) 10 (±4) (n=9) 0.209 
HIV exposed 10 (25) 8 (30.8) 2 (14.3) 0.446 
Sepsis risk at birth 6 (15) 5 (19.2) 1 (7.1) 0.399 
Primary Cause of PPHN  
Any sepsis 7 (17.5) 6 (23) 1 (7) 0.387 
        Confirmed sepsis 1 (2.5) 1 (4) 0 1 
        Congenital pneumonia 2 (5) 2 (8) 0 0.553 
        Presumed sepsis 4 (10) 3 (12) 1 (7) 1 
Intrapartum hypoxia 8 (20) 5 (19.2) 3 (21.4) 1 
All MAS  20 (50) 15 (58) 5 (36) 0.185 
      MAS plus intrapartum 
hypoxia  10 (25)  6 (23)  4 (20) 0.718 
Idiopathic 2 (5) 0 2 (14.3) 0.117 
Pulmonary hypoplasia 3 (7.5) 0 3 (21) 0.037 
*For normally distributed data, PPHN – Persistent pulmonary hypertension of the newborn, HIV – Human 
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2.4.2 Clinical course and short-term outcomes 
 
At the time iNO was commenced, all neonates were receiving an FiO2 of > 0.9, two 
inotropic agents and HFOV. Other aspects of the clinical course and short-term 
outcomes are shown in Table 2.2. 
 
Most neonates were treated with surfactant (maximum of two doses), hydrocortisone 
for hypotension, and sildenafil. Administration of surfactant and sildenafil was 
associated with survival (p=0.003 and p=0.018 respectively). Those who were not 
given surfactant had either pulmonary hypoplasia or idiopathic PPHN. Most of the 
neonates who were treated with sildenafil received it before 48 hours (range 4–96 
hours).  
 
The median age at initiation of iNO was 12 (range 1–60) hours. The median duration 
of iNO was 36 (range 5–192) hours. There was no difference between survivors and 
non-survivors in the proportion of neonates receiving iNO at 48 hours. Survivors 
tended to have a longer duration of iNO treatment (p=0.059). However, the dose of 
iNO at 48 hours was significantly higher in those who died (median doses of 9.2 and 
0 ppm respectively and p=0.044). The median FiO2 at 12 and 24 hours was 












































All three neonates with a 48-hour dose of iNO of ≥ 20 ppm died – ROC and diagt 
analysis showed that this threshold correctly predicted death in 88% of neonates, with 
a sensitivity and a specificity of 43% and 96%; and positive and negative likelihood 
ratios of 22.8 and 0.6 respectively. Similar analysis of FiO2 at 24 hours showed that a 
threshold of 1.0 correctly predicted death in 83% of neonates, with a sensitivity and a 
specificity of 67% and 89%; and positive and negative LRs of 5.8 and 0.4 
respectively. An FiO2 of 1.0 was documented at 24 hours in all three neonates with a 
48 hour iNO dose of ≥ 20 ppm. 
 
The co-morbidities of HIE, IVH, and nosocomial sepsis occurred infrequently.  
Pneumothorax complicated the course of seven neonates (18%) and was strongly 
associated with death (p=0.004) – two of the six affected neonates who died also had 
pulmonary hypoplasia, however the association remained significant when neonates 
with pulmonary hypoplasia were excluded (p=0.021). 
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Table 2.2: Clinical course and short-term outcomes  
iNO – Inhaled nitric oxide, FiO2 – Inspired concentration of oxygen, HIE – Hypoxic ischaemic encephalopathy 
 
 
Sildenafil was prescribed in 65% and 83% of infants before and after the end of 2011 
respectively – these data (together with the absolute numbers of neonates who 
















 Variable All (N=40) Alive (N=26) Dead (N=14) P-Value 
 
Data are n/N (%) or median (IQR as 1st – 3rd 
quartile)  
Surfactant 35/40 (87.5) 26/26 (100) 9/14 (64.2)  0.003 
Hydrocortisone 33/40 (82.5) 21/26 (80.8) 12/14 (85.7) 1.000 
Sildenafil  30/40 (75) 23/26 (88.5) 7/14 (50) 0.018 
Early sildenafil 18/30 (60) 14/23 (60.9) 4/7 (57.1) 1.000 
Age in hours at sildenafil 
initiation 
21.5 (9-48)          
(n=30) 21 (9-48)   (n=23) 
22 (9-36)       
(n=7) 0.902 
Age in hours at iNO 
initiation 
12 (8-24)             
(n=40) 13 (9-24)   (n=26) 
11(6-22)        
(n=14) 0.153 
iNO dose, ppm at 12 hours 
17.5 (11.25-
20)   (n=28) 16 (11-20) (n=19) 
20 (19.2-20)   
(n=9) 0.086 
iNO dose, ppm at 24 hours 
10 (0-15.1)          
(n=34) 9.5 (0-15)  (n=26) 
14.35 (4.1-20) 
(n=8) 0.268 
iNO dose, ppm at 48 hours 
0 (0-9.1)              
(n=32) 0 (0-6)        (n=25) 
9.2 (0-20)        
(n=7) 0.044 
iNO for >48 hours 15/40 (37.5) 10/26 (38.5) 5/14 (35.7) 1.000 
Duration in hours of iNO 
36 (22-60)          
(n=40) 36 (30-72)   (n=26) 
24 (10-60)     
(n=13) 0.079 
Fi02 at 12 hours 
70 (50-100)        
(n=37) 60 (40-95)   (n=25) 
100 (85-100) 
(n=12) 0.007 
Fi02 at 24 hours 
60 (40-100)        
(n=35) 45 (40-80)   (n=26) 
100 (50-100)  
(n=9) 0.017 
HIE/Seizures 4/40 (10) 4/26 (15.4) 0/14 (0) 0.278 
Intraventricular 
haemorrhage 3/40 (7.5) 3/26 (11.5) 0/14 (0) 0.539 
Pneumothorax 7/40 (17.5) 1/26 (3.8) 6/14 (42.9) 0.004 
Nosocomial sepsis 5/40 (12.5) 4/26 (15.4) 1/14 (7.1) 0.640 
	






2.4.3 Sildenafil use and cost of care 
 
The relationships between sildenafil use and the duration of iNO treatment and 
intubation in survivors are shown in Figures 2.2 and 2.3 respectively.  
 
The duration of iNO treatment in the three survivors who did not receive sildenafil 
ranged from 16 to 120 hours. Neonates who were treated with sildenafil early 
required iNO for a median of 36 (IQR 30–46) hours vs. 72 (IQR 36–120) hours in 
those who were treated late (p=0.044).  
 
The duration of intubation (and ventilation) of the three survivors who did not receive 
sildenafil ranged from 3–9 days. Neonates who were treated with sildenafil early 
remained intubated for a median of 3.5 (IQR 3–5) hours vs. 7 (IQR 7–8) hours in 
those who were treated late (p=0.012). There was a significant difference across all 
three categories (p=0.043). 
 
According to the single supplier in South Africa, each cylinder of NO is filled with 
1500 L of gas, and the cost to public hospitals at the time of writing (May 2017), is 
R 11.83/L (before tax). The delivery of approximately 25 ml of NO gas/L ventilator 
gas flow will achieve a dose of 20 ppm. Therefore, the NO consumption at a 
ventilator flow rate of 20 L/minute, is approximately 20 x 0.025 x 60=30 L/hour; this 
equates to a cost of R 355/hour or approximately R 18 per each ppm per hour, but 
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Figure 2.2: Sildenafil and duration of iNO in survivors 
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2.5 DISCUSSION 
 
This retrospective cohort study demonstrates that neonates with PPHN who were 
treated with iNO, in a setting where ECMO was not available, had a high mortality 
(35%). Data of the age at the time of death were not collected. The commonest causes 
of PPHN were MAS and intrapartum hypoxia; and most neonates were out-born. The 
variables significantly associated with death were: pulmonary hypoplasia, 
pneumothorax, absence of sildenafil administration, absence of surfactant 
administration, and maximum doses of FiO2 and iNO at 24 and 48 hours respectively. 
 
The high proportion of out-born neonates (67%) is expected, because neonates with 
PPHN require tertiary care. Studies in developing countries report out-born 
proportions ranging from 28 to 76%.[9,10] There was no association between birth 
weight and mortality in our study – such an association has been reported in preterm 
neonates with PPHN,[8] but we did not include neonates under 35 weeks’ gestation. 
 
The high mortality and the frequency of MAS and intrapartum hypoxia are in keeping 
with findings from other studies in developing countries[7,9-11] – in contrast to 
developed countries, where sepsis is causal in the majority of cases of PPHN.[8] The 
role of intrapartum hypoxia as a primary cause may have been under-estimated in our 
study due to the frequent co-existence of MAS and intrapartum hypoxia. Moreover, 
only half of the cohort had early blood gas data, possibly due to the lack blood gas 
machines at the birth sites of the out-born neonates. 
 
Idiopathic PPHN is associated with normal lung parenchyma and abnormal 
remodeling of the fetal pulmonary vasculature.[3] The low birth weight of one of the 
two infants with idiopathic PPHN in our study may represent an associated chronic 
underlying cause – inborn errors of metabolism and abnormal genetic mutations 
causing ‘idiopathic’ PPHN and low birth weight have been described.[14] Data from 
animal studies suggest an association between idiopathic PPHN and maternal non-
steroidal anti-inflammatories (NSAIDs) or selective serotonin reuptake inhibitor 
(SSRI) antidepressants, but human data are limited and conflicting.[15]   
 
Pulmonary hypoplasia was an uncommon cause of PPHN, but it was the only cause 
associated with mortality – this is in keeping with the published literature, which 
shows a high mortality worldwide.[16] The diagnosis was a clinical one, based on 
small lung fields relative to ventilation, and may have been subject to observer bias. 
One of the neonates had pulmonary hypoplasia secondary to CDH. This neonate was 
born in 2010 when iNO was still used for CDH in GSH; that approach was possibly 
based on a report at the time showing potential benefit[17] and a guideline that 
supported iNO use in some situations.[18] The unit practice changed from 2011 after 
reviewing previous, more robust evidence suggesting lack of efficacy[19]; thereafter, 
neonates with CDH were no longer treated with iNO. A recent update of this evidence 
supports the continued stance of not treating CDH with iNO.[20] 
 
Pneumothorax was the only morbidity associated with death. In two of these neonates 
it complicated pulmonary hypoplasia, which is well described,[21,22] but may be a 
confounder. However, even when these patients were excluded, pneumothorax was 
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still significantly associated with death (p=0.021). A study of PPHN in Thailand 
found a similar association.[10] 
 
Treatment with surfactant in our cohort was strongly associated with survival; this 
was probably due to the fact that three of the five neonates who did not receive 
surfactant had pulmonary hypoplasia, which is independently associated with a high 
mortality rate.[16] When the analysis was repeated with these three infants excluded, 
the association was no longer significant (p=0.083). Surfactant administration to term 
infants with PPHN has been shown to reduce the need for ECMO when parenchymal 
disease is present (the majority of our cohort) but, similar to iNO, it has not been 
shown to decrease mortality.[23] A recent meta-analysis of surfactant for MAS found 
that although hospital stay and the requirement for ECMO were significantly reduced, 
there was no effect on mortality, morbidity or duration of ventilation.[24] A Cochrane 
review in 2012 was unable to identify any suitable studies to determine if surfactant 
was beneficial to term and near-term neonates with pneumonia.[25] 
 
Most infants in the cohort were treated with hydrocortisone for refractory hypotension 
– this approach is supported by limited neonatal data,[26] but is in keeping with global 
trends.[27] Although glucocorticoids are not recommended for improving respiratory 
outcomes of MAS,[28-30] hydrocortisone has been shown to improve oxygenation and 
reduce pulmonary vasoconstrictor levels in lambs with PPHN[31]; and two small 
randomised controlled trials, enrolling non-intubated neonates with MAS, found that 
both intravenous methylprednisone and inhaled budesonide resulted in improved 
oxygenation and shorter hospital stays with no effect on mortality.[32,33]  
 
The neonates in our cohort who died tended to have a shorter duration of iNO, despite 
it being initiated at a similar time to survivors – this is probably due to early death 
(seven of the 14 neonates who died, did so before 48 hours) and/or early cessation of 
iNO due to lack of effect. A poor response to iNO in those who were still alive at  
48 hours, but died later, is suggested by the significantly higher dose of iNO in non-
survivors vs. survivors (median 9.2 and 0 ppm respectively); an iNO dose of 
 ≥ 20 ppm at 48 hours correctly predicted death in 88% of neonates. Most of the non-
responders (i.e. those who did not survive) in this cohort could probably have been 
identified earlier by the persistently high FiO2 at 24 hours. The infants who died had a 
significantly higher FiO2 at 24 hours compared to survivors (median 0.45 and 1.0 
respectively); an FiO2 of 1.0 at 24 hours correctly predicted death in 83% of infants. 
 
There are few published data on the use of sildenafil together with iNO, specifically 
for PPHN, and none on the effect that combining these has on mortality for this 
condition.[10] The authors of a Cochrane review concluded that sildenafil may be used 
in resource-limited environments, but they make no recommendation for the use of 
sildenafil with iNO.[34] Data from animal models and small studies in infants post 
cardiac surgery suggest that when iNO and sildenafil are used together, a significant 
drop in systemic oxygenation and blood pressure can occur.[35,36] 
 
The data from this study indicate a significant reduction in mortality in those who 
were treated with sildenafil, but these data are difficult to interpret because some 
neonates with persistent refractory hypotension may not have received sildenafil due 
to concerns about potential exacerbation of hypotension.  However, this confounding 
effect is unlikely to be substantial because the majority of neonates were treated with 
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sildenafil, particularly in the last 3 years (83%); and most neonates who received 
hydrocortisone also received sildenafil. Data showing the earlier weaning of iNO and 
the shorter periods of ventilation experienced by the neonates who were treated earlier 
compared to those who were treated later, may have been confounded by similar 
selection bias. In 2015, Limjoco and co-authors published data showing that the 
practice of withholding enteral sildenafil from hypotensive neonates with PPHN may 
not be appropriate; they described a cohort of 17 neonates treated with iNO, inotropes 
and enteral sildenafil – there was no significant decrease in blood pressure, nor 
increase in inotrope requirement after treatment with sildenafil, but there was a wide 
variation in the extent of inotrope treatment.[37]  
 
Currently, iNO costs R18 per ppm per hour. The cost of iNO at 20 ppm is therefore 
R8 640 per day. Since all neonates in our cohort with this requirement at 48 hours 
died and also had FiO2 of 1.0 at 24 hours, these neonates should be considered as 
non-responders – substantial cost savings could be made by stopping iNO at 48 hours 
or earlier. The shorter duration of iNO in those who received early sildenafil (median 
36 vs. 72 hours) may represent a potential cost-saving of between R3 196 (at 5 ppm 
for 36 hours) and R12 780 (at 20 ppm for 36 hours) per patient. These numbers are 
subject to inaccuracies due to circuit leaks, different types of ventilators, incorrect 
monitoring, or faulty equipment. Sildenafil was also associated with a reduced time to 
extubation, which suggests further potential cost savings. 
 
In addition to the potential selection bias associated with Sildenafil treatment, this 
study has further limitations: the small cohort size and wide confidence intervals; and 
the lack of data regarding the reason for not using sildenafil, make the associated 
outcomes difficult to interpret. The lack of data regarding the oxygenation index 
makes it difficult to ascertain which infants would have benefited from ECMO. In 
addition, the multiple drugs and treatment modalities may have introduced the 
potential for confounding the effects of iNO. To eliminate them all to assess pure 
survival in iNO at different doses, however, would have been impossible.	
 
Despite the limitations, this is the first study (to our knowledge) in sub-Saharan 
Africa to document outcomes of neonates with PPHN who were treated with iNO and 
sildenafil; and it describes data from a sufficient period to detect changes in clinician 
prescribing behavior. Another strength of this study is that it identifies robust clinical 
markers that strongly predict a poor outcome at 24 and 48 hours and it provides some 




The treatment of PPHN with iNO in the absence of ECMO was associated with a high 
mortality, particularly in neonates with congenital lung abnormalities. An FiO2 of 1.0 
at 24 hours and an iNO dose of ≥ 20ppm at 48 hours could be used to identify 
neonates who are unlikely to benefit from treatment, particularly when both are 
present.  The combination of iNO with Sildenafil may be associated with cost-
effective care and improved short term outcomes, but a formal cost-saving analysis is 
needed to confirm this due to the presence of many other factors. 
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These findings provide a potential basis for cost-saving measures and resource 
allocation. The combination of iNO and sildenafil as treatment for neonates with 
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◦ Objectives: what the study intends to find out  
◦ Methods: must include study design, number of participants, description of the intervention, primary 
and secondary outcomes, any specific analyses that were done on the data.  
◦ Results: first sentence must be brief population and sample description; outline the results according 
to the methods described. Primary outcomes must be described first, even if they are not the most 
significant findings of the study.  
◦ Conclusion: must be supported by the data, include recommendations for further study/actions.  
• Please ensure that the structured abstract is complete, accurate and clear and has been approved by all 
authors.  
• Do not include any references in the abstracts.  
Here is an example of a good abstract:  
Background. Despite enormous strides in preventing hepatitis B virus (HBV) infection, perinatal 
transmission still contributes significantly to HBV epidemiology worldwide; this could account for 
approximately 50% of chronically infected individuals.  
Objective. To assess the need for HBV screening in antenatal clinics in the HIV/AIDS era.  
Methods. This was a retrospective study conducted at the antenatal clinic of 1 Military Hospital, 
Tshwane, South Africa. Laboratory data for HBV, HIV and CD4 count were obtained and analysed for 
the period January 2008  December 2013.  
Results. A total of 2 513 patients’ results were retrieved and 2 368 patients were enrolled as both their 
HBV and HIV serology results were available. The mean age of participants was 29 years (range 14  
46). HIV prevalence in this study was 20.5% (95% confidence interval (CI) 0.189  0.222). The median 
CD4 count in HIVinfected patients was 522 cells/μL (interquartile range 370  711). There was an 
overall HBV prevalence of 0.8% (95% CI 0.005  0.011). The hepatitis B surface antigen (HBsAg) 
prevalence was significantly higher (2.1%) among HIV coinfected compared with HIVuninfected 
patients (0.4%) (p=0.0001). Hepatitis e antigen (HBeAg) positivity was 30% in the HIV coinfected 
compared with 37.6% in the HIVuninfected individuals (p=0.7400).  
Conclusion. This study showed a significantly higher HBV prevalence in HIVinfected compared with 
HIVuninfected patients. The comparable HBeAg prevalence between the two groups indicates that 
both were at an increased risk of vertical transmission, therefore demonstrating a need for antenatal 
screening for HBV. Since antenatal screening is often not affordable in lowincome countries, 
administration of HBV vaccine at birth is needed for prevention of vertical transmission.  
Main article  
All articles are to include the following main sections:  
Introduction/Background, Methods, Results, Discussion, Conclusions.  
The following are additional heading or section options that may appear within these:  
• Objectives (within Introduction/Background): a clear statement of the main aim of the study and the 
major hypothesis tested or research question posed  
• Design (within Methods): including factors such as prospective, randomisation, blinding, placebo 
control, case control, crossover, criterion standards for diagnostic tests, etc.  
• Setting (within Methods): level of care, e.g. primary, secondary, number of participating centres.  
• Participants (instead of patients or subjects; within Methods): numbers entering and completing the 
study, sex, age and any other biological, behavioural, social or cultural factors (e.g. smoking status, 
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socioeconomic group, educational attainment, co-existing disease indicators, etc)that may have an 
impact on the study results. Clearly define how participants were enrolled, and describe selection and 
exclusion criteria.  
• Interventions (within Methods): what, how, when and for how long. Typically for randomised 
controlled trials, crossover trials, and before and after studies.  
• Main outcome measures (within Methods): those as planned in the protocol, and those ultimately 
measured. Explain differences, if any.  
Results  
• Start with description of the population and sample. Include key characteristics of comparison groups.  
• Main results with (for quantitative studies) 95% confidence intervals and, where appropriate, the 
exact level of statistical significance and the number need to treat/harm. Whenever possible, state 
absolute rather than relative risks.  
• Do not replicate data in tables and in text.  
• If presenting mean and standard deviations, specify this clearly. Our house style is to present this as 
follows:  
• E.g.: The mean (SD) birth weight was 2 500 (1 210) g. Do not use the ± symbol for mean (SD).  
• Leave interpretation to the Discussion section. The Results section should just report the findings as 
per the Methods section.  
Discussion  
Please ensure that the discussion is concise and follows this overall structure – sub-headings are not 
needed:  
• Statement of principal findings  
• Strengths and weaknesses of the study  
• Contribution to the body of knowledge  
• Strengths and weaknesses in relation to other studies  
• The meaning of the study – e.g. what this study means to clinicians and policymakers  
• Unanswered questions and recommendations for future research  
Conclusions  
This may be the only section readers look at, therefore write it carefully. Include primary conclusions 
and their implications, suggesting areas for further research if appropriate. Do not go beyond the data 
in the article.  
Illustrations/photos/scans  
• If illustrations submitted have been published elsewhere, the author(s) should provide consent to 
republication obtained from the copyright holder.  
• Figures must be numbered in Arabic numerals and referred to in the text e.g. '(Fig. 1)'.  
• Each figure must have a caption/legend: Fig. 1. Description (any abbreviations in full).  
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• All images must be of high enough resolution/quality for print.  
• All illustrations (graphs, diagrams, charts, etc.) must be in PDF or jpeg form.  
• Ensure all graph axes are labelled appropriately, with a heading/description and units (as necessary) 
indicated. Do not include decimal places if not necessary e.g. 0; 1.0; 2.0; 3.0; 4.0 etc.  
• Scans/photos showing a specific feature e.g. Intermediate magnification micrograph of a low 
malignant potential (LMP) mucinous ovarian tumour. (H&E stain). –include an arrow to show the 
tumour.  
• Each image must be attached individually as a 'supplementary file' upon submission (not solely 
embedded in the accompanying manuscript) and named Fig. 1, Fig. 2, etc.  
Tables  
• Tables should be constructed carefully and simply for intelligible data representation. Unnecessarily 
complicated tables are strongly discouraged.  
• Large tables will generally not be accepted for publication in their entirety. Please consider 
shortening and using the text to highlight specific important sections, or offer a large table as an 
addendum to the publication, but available in full on request from the author  
• Embed/include each table in the manuscript Word file - do not provide separately as supplementary 
files.  
• Number each table in Arabic numerals (Table 1, Table 2, etc.) and refer to consecutively in the text.  
• Tables must be cell-based (i.e. not constructed with text boxes or tabs) and editable.  
• Ensure each table has a concise title and column headings, and include units where necessary.  
• Footnotes must be indicated with consecutive use of the following symbols: * † ‡ § ¶ ||  
then ** †† ‡‡ etc.  
Do not: Use [Enter] within a row to make ‘new rows’:  
Rather:  
Each row of data must have its own proper row:  
Do not: use separate columns for n and %:  
Rather:  
Combine into one column, n (%):  
Do not: have overlapping categories, e.g.:  
Rather:  
Use <> symbols or numbers that don’t overlap:  
References  
NB: Only complete, correctly formatted reference lists in Vancouver style will be accepted. Reference 
lists must be generated manually and not with the use of reference manager software. Endnotes must 
not be used.  
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• Authors must verify references from original sources.  
• Citations should be inserted in the text as superscript numbers between square brackets, e.g. These 
regulations are endorsed by the World Health Organization,[2] and others.[3,4-6]  
• All references should be listed at the end of the article in numerical order of appearance in the 
Vancouver style (not alphabetical order). • Approved abbreviations of journal titles must be used; see 
the List of Journals in Index Medicus.  
• Names and initials of all authors should be given; if there are more than six authors, the first three 
names should be given followed by et al.  
• Volume and issue numbers should be given.  
• First and last page, in full, should be given e.g.: 1215-1217 not 1215-17.  
• Wherever possible, references must be accompanied by a digital object identifier (DOI) link). 
Authors are encouraged to use the DOI lookup service offered by CrossRef:  
On the Crossref homepage, paste the article title into the ‘Metadata search’ box.  
Look for the correct, matching article in the list of results.  
Click Actions > Cite  
Alongside 'url =' copy the URL between { }. Provide as follows, e.g.: 
https://doi.org/10.7196/07294.937.98x  
Some examples:  
• Journal references: Price NC, Jacobs NN, Roberts DA, et al. Importance of asking about glaucoma. 
Stat Med 1998;289(1):350-355. http://dx.doi.org/10.1000/hgjr.182  
• Book references: Jeffcoate N. Principles of Gynaecology. 4th ed. London: Butterworth, 1975:96-101.  
• Chapter/section in a book: Weinstein L, Swartz MN. Pathogenic Properties of Invading 
Microorganisms. In: Sodeman WA, Sodeman WA, eds. Pathologic Physiology: Mechanisms of 
Disease. Philadelphia: WB Saunders, 1974:457-472.  
• Internet references: World Health Organization. The World Health Report 2002 - Reducing Risks, 
Promoting Healthy Life. Geneva: WHO, 2002. http://www.who.int/whr/2002  
(accessed 16 January 2010).  
• Legal references  
• Government Gazettes:  
National Department of Health, South Africa. National Policy for Health Act, 1990 (Act No. 116 of 
1990). Free primary health care services. Government Gazette No. 17507:1514. 1996.  
In this example, 17507 is the Gazette Number. This is followed by :1514 - this is the notice number in 
this Gazette.  
• Provincial Gazettes:  
Gauteng Province, South Africa; Department of Agriculture, Conservation, Environment and Land 
Affairs. Publication of the Gauteng health care waste management draft regulations. Gauteng 
Provincial Gazette No. 373:3003, 2003.  
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• Acts:  
South Africa. National Health Act No. 61 of 2003.  
• Regulations to an Act:  
South Africa. National Health Act of 2003. Regulations: Rendering of clinical forensic medicine 
services. Government Gazette No. 35099, 2012. (Published under Government Notice R176).  
• Bills:  
South Africa. Traditional Health Practitioners Bill, No. B66B-2003, 2006.  
• Green/white papers:  
South Africa. Department of Health Green Paper: National Health Insurance in South Africa. 2011.  
• Case law:  
Rex v Jopp and Another 1949 (4) SA 11 (N)  
Rex v Jopp and Another: Name of the parties concerned  
1949: Date of decision (or when the case was heard)  
(4): Volume number  
SA: SA Law Reports  
11: Page or section number  
(N): In this case Natal - where the case was heard. Similarly, (C) woud indicate Cape, (G) Gauteng, 
and so on.  
NOTE: no . after the v  
• Other references (e.g. reports) should follow the same format: Author(s). Title. Publisher place: 
Publisher name, year; pages.  
• Cited manuscripts that have been accepted but not yet published can be included as references 
followed by '(in press)'.  
• Unpublished observations and personal communications in the text must not appear in the reference 
list. The full name of the source person must be provided for personal communications e.g. '...(Prof. 
Michael Jones, personal communication)'.  
 
 
	
